Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene

(2011) A. K. Murugan et al.   CANCER RESEARCH

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking

(2011) P Mazot et al.   ONCOGENE

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

(2011) R. Katayama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

(2010) Christian C. Lee et al.   BIOCHEMICAL JOURNAL

Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors

(2010) Roberto T. Bossi et al.   BIOCHEMISTRY

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

(2010) T. Sasaki et al.   CANCER RESEARCH

Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy

(2010) T. Martinsson et al.   CANCER RESEARCH

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

(2010) S. De Brouwer et al.   CLINICAL CANCER RESEARCH

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic lymphoma kinase: signalling in development and disease

(2009) Ruth H. Palmer et al.   BIOCHEMICAL JOURNAL

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

(2009) Michael J. Eck et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

(2009) P. Sabbatini et al.   MOLECULAR CANCER THERAPEUTICS

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

(2008) Helena Carén et al.   BIOCHEMICAL JOURNAL

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE

Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma

(2008) Wendy L. Hobbie et al.   PEDIATRIC BLOOD & CANCER

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA